Antiangiogenic therapies are used in multiple adult cancer indications, although, to our knowledge, to date, none has demonstrated clear benefit in pediatric cancers.12-14 Preclinical in vitro and in vivo data of bevacizumab (B; a monoclonal antibody against vascular endothelial growth factor [VEGF]) as single agent and in combination, including irinotecan-temozolomide (IT) as well as other anti-VEGF therapies, support the evaluation of antiangiogenic agents in neuroblastoma.15-22 B is among the most established of antiangiogenic drugs and has gained approval in many adult indications. Here, VEGFA is linked to cancer.